康方生物-B(09926.HK)啟動一線治療晚期胃腺癌或胃食管結合部腺癌III期臨床研究
康方生物-B(09926.HK)公布,公司已經獲得國家藥品監督管理局同意,開展其自主研發的全球首創新型腫瘤免疫治療新藥Cadonilimab(PD-1/CTLA-4雙特異性抗體,研發代號:AK104)聯合奧沙利鉑和卡培他濱(「XELOX」)對比安慰劑聯合XELOX一線治療晚期胃腺癌或胃食管結合部腺癌的III期關鍵性註冊性臨床研究(臨床登記號:CTR20211567),並順利召開全國研究者會議。
該臨床研究是一項比較AK104聯合XELOX方案與安慰劑聯合XELOX方案作為一線治療不可手術切除的局部晚期或轉移性胃腺癌或胃食管結合部腺癌的有效性與安全性的隨機、雙盲、多中心、III期臨床研究。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.